Eli Lilly's oral GLP-1 weight loss medication approved for sale in the U.S. and has submitted an application for approval in China

2026-04-03 04:29:03

People’s Finance & News April 2 reported that on April 1, local time, Eli Lilly announced that its oral small-molecule GLP-1 receptor agonist orforglipron has been approved by the U.S. FDA for marketing to treat adult obesity or overweight, which also became the second orally administered GLP-1 weight-loss drug to be launched globally. Eli Lilly’s orforglipron has already submitted applications for marketing for weight loss or glucose-lowering in more than 40 countries worldwide. At the end of last year, the drug was also submitted to the China National Medical Products Administration for marketing applications to treat type 2 diabetes and obesity. (First Financial)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.